

HLAVNÍ TÉMA

VÝZNAM MIKROBIOMU U HEMATOONKOLOGICKÝCH PACIENTŮ

5. Long Y, Tang L, Zhou Y, et al. Causal relationship between gut microbiota and cancers: a two-sample Mendelian randomisation study. *BMC Med.* 2023;21(1):66.

6. Zhou L, Zhang M, Wang Y, et al. *Faecalibacterium prausnitzii* Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1. *Inflamm Bowel Dis.* 2018;24(9):1926-1940.

7. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature.* 2013;504(7480):446-450.

8. Garrett WS. Cancer and the microbiota. *Science.* 2015;348(6230):80-86.

9. Guevara-Ramírez P, Cadena-Ullauri S, Paz-Cruz E, et al. Role of the gut microbiota in hematologic cancer. *Front Microbiol.* 2023;14:1185787.

10. Huang X, Cai H, Zhao Y, et al. The Gut Microbiome and Acute Leukemia: Implications for Early Diagnostic and New

Therapies. *Mol Nutr Food Res.* 2023;e2300551.

11. Pflug N, Kluth S, Vehreschild JJ, et al. Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. *Oncoimmunology.* 2016;5(6):e1150399.

12. Yoon SE, Kang W, Choi S, et al. The influence of microbial dysbiosis on immunotherapy-related efficacy and safety in diffuse large B-cell lymphoma. *Blood.* 2023;141(18):2224-2238.

13. Pianko MJ, Devlin SM, Littmann ER, et al. Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. *Blood Adv.* 2019;3(13):2040-2044.

14. Morales ML, Ferrer-Marín F. Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them? *Cancers.* 2023;15(4):1348.

15. Jiang H, Zhao X, Zang M, et al. Gut Microbiome and Plas-

ma Metabolomic Analysis in Patients with Myelodysplastic Syndrome. *Oxid Med Cell Longev.* 2022;2022:1482811.

16. Wang R, Yang X, Liu J, et al. Gut microbiota regulates acute myeloid leukaemia via alteration of intestinal barrier function mediated by butyrate. *Nat Commun [Internet].* 2022 [cited 2024 Jan 30];13. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085760/>.

17. Khan N, Lindner S, Gomes ALC, et al. Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. *Blood.* 2021;137(11):1527-1537.


18. Asokan S, Cullin N, Stein-Thoeringer CK, et al. CAR-T Cell Therapy and the Gut Microbiota. *Cancers.* 2023;15(3):794.

19. Jiang H, Zhang Q. Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review). *Oncol Lett.* 2024;27(2):87.

Onkologie na rok 2024

Už máte předplaceno?

 **SOLEN**
let s vámi



PŘEDPLATNÝM ČASOPISU NA ROK 2024 ZÍSKÁTE

5 čísel ve vaší schránce

Tematická suplementa

Čtení na tabletech,
PC a telefonech

Přístup do archivu
časopisu on-line

Cena předplatného
na rok 2024: 1 350 Kč

OBJEDNÁVEJTE

www.onkologiecs.cz

předplatne@solen.cz

585 204 335

